As described in Note 2, "Revisions of Previously-Issued Financial Statements", amounts presented below reflect revisions to correct certain immaterial errors related to sales allowance.

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2018			2018			2017			2017
Molecular diagnostic testing	$	187.6		$	177.3		$	177.9		$	176.5
Pharmaceutical and clinical services		13.3			13.8			14.8			11.4
Total Revenue		200.9			191.1			192.7			187.9
Costs and expenses:
Cost of molecular diagnostic testing		38.0			36.8			37.7			36.2
Cost of pharmaceutical and clinical services		7.7			7.3			6.7			6.8
Research and development expense		17.7			18.5			16.8			17.8
Change in the fair value of contingent consideration		0.2			(1.2	)		13.0			(73.2	)
Selling, general and administrative expense		121.4			115.1			115.4			115.2
Total costs and expenses		185.0			176.5			189.6			102.8
Operating income		15.9			14.6			3.1			85.1
Other income (expense):
Interest income		0.5			0.5			0.4			0.4
Interest expense		(1.1	)		(0.5	)		(0.7	)		(0.9	)
Other		0.8			(0.5	)		(0.4	)		(0.3	)
Total other income (expense)		0.2			(0.5	)		(0.7	)		(0.8	)
Income before income taxes		16.1			14.1			2.4			84.3
Income tax provision		3.0			4.5			(26.3	)		4.8
Net income		13.1			9.6			28.7			79.5
Net loss attributable to non-controlling interest		-			(0.1	)		-			(0.1	)
Net income attributable to Myriad Genetics, Inc. stockholders	$	13.1		$	9.7		$	28.7		$	79.6
Earnings per share:
Basic	$	0.19		$	0.14		$	0.41		$	1.16
Diluted	$	0.18		$	0.13		$	0.40		$	1.13
Weighted average shares outstanding:
Basic		70.1			69.8			69.3			68.6
Diluted		72.9			72.4			71.9			70.4

In millions, except per share amounts	Quarters Ended
	Jun 30,			Mar 31,			Dec 31,			Sep 30,
Consolidated Statement of Operations Data:	2017			2017			2016			2016
Molecular diagnostic testing	$	187.0		$	183.0		$	184.1		$	166.5
Pharmaceutical and clinical services		12.6			11.7			12.6			12.4
Total Revenue		199.6			194.7			196.7			178.9
Costs and expenses:
Cost of molecular diagnostic testing		35.6			37.9			37.4			34.3
Cost of pharmaceutical and clinical services		6.9			6.4			7.0			5.7
Research and development expense		18.8			17.6			18.6			19.4
Change in contingent consideration		(2.7	)		5.2			(3.8	)		0.5
Selling, general and administrative expense		122.1			122.1			120.3			111.9
Total costs and expenses		180.7			189.2			179.5			171.8
Operating income		18.9			5.5			17.2			7.1
Other income (expense):
Interest income		0.3			0.3			0.3			0.3
Interest Expense		(1.2	)		(1.5	)		(2.6	)		(0.7	)
Other		(0.1	)		1.5			(2.6	)		(1.8	)
Total other income (expense)		(1.0	)		0.3			(4.9	)		(2.2	)
Income before income taxes		17.9			5.8			12.3			4.9
Income tax provision		5.8			3.0			6.2			5.6
Net income	$	12.1		$	2.8		$	6.1		$	(0.7	)
Net loss attributable to non-controlling interest		(0.2	)		-			-			-
Net income attributable to Myriad Genetics, Inc. stockholders	$	12.3		$	2.8		$	6.1		$	(0.7	)
Earnings per share:
Basic	$	0.18		$	0.04		$	0.09		$	(0.01	)
Diluted	$	0.18		$	0.04		$	0.09		$	(0.01	)
Weighted average shares outstanding:
Basic		68.2			68.1			68.2			68.8
Diluted		68.9			68.3			68.3			68.8